These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20494407)

  • 1. Anakinra's efficacy is variable in refractory gout: report of ten cases.
    Chen K; Fields T; Mancuso CA; Bass AR; Vasanth L
    Semin Arthritis Rheum; 2010 Dec; 40(3):210-4. PubMed ID: 20494407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1 inhibition with anakinra in a patient with refractory gout.
    Singh D; Huston KK
    J Clin Rheumatol; 2009 Oct; 15(7):366. PubMed ID: 20009976
    [No Abstract]   [Full Text] [Related]  

  • 3. Case of anakinra as a steroid-sparing agent for gout inflammation.
    Gratton SB; Scalapino KJ; Fye KH
    Arthritis Rheum; 2009 Sep; 61(9):1268-70. PubMed ID: 19714614
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
    Tran AP; Edelman J
    Int J Rheum Dis; 2011 Aug; 14(3):e33-7. PubMed ID: 21816011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Anakinra in Acute Gout: A Retrospective Review of Initial and Refractory Therapy.
    Petite SE
    Am J Ther; 2017; 24(5):e633-e634. PubMed ID: 27763889
    [No Abstract]   [Full Text] [Related]  

  • 6. First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine.
    Funck-Brentano T; Salliot C; Leboime A; Zafrani L; Servais A; Larousserie F; Dougados M
    Rheumatology (Oxford); 2011 Mar; 50(3):622-4. PubMed ID: 21097448
    [No Abstract]   [Full Text] [Related]  

  • 7. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 8. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center.
    Desmarais J; Chu CQ
    J Rheumatol; 2019 Jul; 46(7):748-750. PubMed ID: 30442822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout, chronic kidney disease, and aplastic anemia.
    Bartov JB; Ali Y
    J Clin Rheumatol; 2013 Dec; 19(8):454-6. PubMed ID: 24263151
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.
    Botsios C; Sfriso P; Ostuni PA; Todesco S; Punzi L
    Rheumatology (Oxford); 2007 Jun; 46(6):1042-3. PubMed ID: 17449489
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra.
    Ghosh P; Cho M; Rawat G; Simkin PA; Gardner GC
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1381-4. PubMed ID: 23650178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome.
    Kluger N; Rivière S; Guillot B; Bessis D
    Acta Derm Venereol; 2008; 88(3):287-8. PubMed ID: 18480937
    [No Abstract]   [Full Text] [Related]  

  • 15. Anakinra in resistant gout: a case report.
    Van Wabeke J; Dhondt E; Peene I; Piette Y
    Acta Clin Belg; 2017 Aug; 72(4):293-295. PubMed ID: 27712511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.
    Moltó A; Ea HK; Richette P; Bardin T; Lioté F
    Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission of Schnitzler syndrome after treatment with anakinra.
    Frischmeyer-Guerrerio PA; Rachamalla R; Saini SS
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):617-9. PubMed ID: 18592830
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.
    Brenner M; Ruzicka T; Plewig G; Thomas P; Herzer P
    Br J Dermatol; 2009 Nov; 161(5):1199-201. PubMed ID: 19673875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schnitzler syndrome: response to anakinra in two cases and a review of the literature.
    Schuster C; Kränke B; Aberer E; Arbab E; Sturm G; Aberer W
    Int J Dermatol; 2009 Nov; 48(11):1190-4. PubMed ID: 20064173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
    Calvo-Aranda E; Sanchez-Aranda FM
    Rheumatology (Oxford); 2021 Nov; 60(11):e375-e377. PubMed ID: 34009241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.